Current Edition

Boehringer Ingelheim

Boehringer Ingelheim takes next step in development of cystic fibrosis gene therapy

Boston biotech Vertex is the leading developer of cystic fibrosis medicines. Its four approved drugs can treat most patients. Trikafta, the one most recently approved …

Continue Reading →

Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

Vertex is best known for its work in cystic fibrosis, having developed four approved medicines that, by the company’s estimates, can treat about 90% of …

Continue Reading →